Nu‑Med Plus suspends development; $863 cash, going‑concern warning, seeks $1.2M

Nu-Med Plus, Inc. (OTCMKTS: NUMD) - Quick company snapshot and income-statement takeaways.

What's happening inside the company
* Management has suspended product development until fresh capital is raised.
* Company acknowledges substantial doubt about its ability to continue as a going concern - funded only through September 30, 2025 without new financing.
* Reliance on related‑party funding and officer loans; $14,000 received subsequent to June 30, 2025 ($12,500 from CEO William Hayde; $1,500 from CFO Keith Merrell).
* Internal disclosure controls were judged not effective as of June 30, 2025.

Income statement - positives
* Operating expenses fell year‑over‑year: Six months ended June 30, 2025 operating expenses $29,119 vs $36,619 in 2024 (improvement of $7,500).
* Quarterly improvement: three months ended June 30, 2025 operating expenses $10,419 vs $16,040 in prior year quarter.
* Net loss narrowed vs prior year: six months net loss $(31,598) in 2025 vs $(39,112) in 2024; three months $(11,665) vs $(17,287).

Income statement - negatives
* No revenue reported for the three- or six‑month periods - company remains pre‑revenue.
* Net loss continues (six months $(31,598)); basic and diluted loss per share listed as $0.00 due to rounding but loss exists.
* Interest expense persists (six months $2,479) and a $100,000 related‑party note is outstanding (matures December 31, 2025).
* Cost control improvements are small relative to cash shortfall and development funding needs.

Key reported figures (as stated)
* Cash at June 30, 2025: $863.
* Total assets: $8,163. Total current assets: $8,163.
* Total liabilities: $254,857. Working capital deficiency / total stockholders' deficit: $(246,694).
* Accounts payable: $55,204; Accounts payable - related party: $86,160.
* Note payable: $100,000 (to YourSpace America, Inc.; CEO Hayde is Chairman of YSA).
* Accumulated deficit: $(9,924,930).
* Shares outstanding (Aug 11, 2025): 83,548,469 shares (common).
* Net loss: Three months ended June 30, 2025 $(11,665); Six months $(31,598).
* Cash used in operating activities (six months): $(1,510).
* Management's stated funding need: approximately $1,200,000 for the next 12 months (company says it is currently funded through 9/30/2025).
* Subsequent event: $14,000 contributed by officers after 6/30/25.

What to watch (near term)
* Financing activity - any announced capital raise, related‑party loans, or private placements (company needs ~$300k for overhead + ~$900k for development).
* Status of the $100,000 note due 12/31/2025 and related‑party exposure.
* Any change from "development suspended" to active spending-would require visible funding source.
* SEC filings for updated cash runway / material events; improvements to disclosure controls.

Bottom line
Nu‑Med Plus is an early‑stage, pre‑revenue medical device developer with modest expense reductions but critically low cash and a large accumulated deficit. The company's immediate survival hinges on raising meaningful capital soon. Investors should treat NUMD as a high‑risk, capital‑dependent micro‑cap where dilution, related‑party funding and going‑concern risk are primary concerns.

All figures and statements above are drawn directly from Nu‑Med Plus, Inc.'s Form 10‑Q for the quarter ended June 30, 2025.